Papillary serous endometrial carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:31 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Papillary serous endometrial carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Azenosertib (ZN-c3) for Women with Recurrent or Persistent Uterine Serous Carcinoma https://clinicaltrials.eu/trial/study-of-azenosertib-zn-c3-for-women-with-recurrent-or-persistent-uterine-serous-carcinoma/ Wed, 29 Apr 2026 14:30:42 +0000 https://clinicaltrials.eu/trial/study-of-azenosertib-zn-c3-for-women-with-recurrent-or-persistent-uterine-serous-carcinoma/ This clinical trial is focused on studying a type of cancer called uterine serous carcinoma, which is a form of endometrial cancer that can be difficult to treat when it comes back or doesn’t go away. The study is testing a new treatment called azenosertib, also known by its code name ZN-c3. This medication is being evaluated to see how safe it is and how well it works in treating this specific type of cancer.

The trial will involve taking the medication in the form of a film-coated tablet. Participants will be monitored to understand how their bodies respond to the treatment and to check for any side effects. The study aims to gather information on the medication’s ability to reduce or control the cancer and to assess its overall safety for patients.

Throughout the study, participants will receive regular check-ups and tests to track their progress. The goal is to determine if ZN-c3 can be a beneficial treatment option for women with recurrent or persistent uterine serous carcinoma, providing new hope for those who have limited treatment options. The study will also compare the effects of ZN-c3 with other treatments, including a placebo, to ensure comprehensive results.

]]>